Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Dorzagliatin - Hua Medicine

Drug Profile

Dorzagliatin - Hua Medicine

Alternative Names: Doglietin; doxagliestatin; Doxgliatine; HMS-5552; HuaTangNing; RO-5305552; Sinogliatin

Latest Information Update: 27 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Roche
  • Developer Hua Medicine
  • Class Acetamides; Antihyperglycaemics; Chlorobenzenes; Phenyl ethers; Pyrazoles; Pyrroles; Small molecules
  • Mechanism of Action Glucokinase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Diabetic nephropathies; Type 2 diabetes mellitus
  • Preclinical Type 1 diabetes mellitus

Most Recent Events

  • 27 Nov 2023 Launched for Diabetic nephropathies (Combination therapy) in China (PO) (Hua Medicine pipeline, November 2023)
  • 27 Nov 2023 Launched for Diabetic nephropathies in China (PO) (Hua Medicine pipeline, November 2023)
  • 23 Jun 2023 Efficacy data from a phase I trial in Type 2 diabetes mellitus presented at the 83rd Annual Scientific Sessions of the American Diabetes Association (ADA-2023)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top